



## 5.60.005

**Section:** Prescription Drugs      **Effective Date:** January 1, 2026

**Subsection:** Central Nervous System Drugs      **Original Policy Date:** June 6, 2014

**Subject:** Xyrem      **Page:** 1 of 6

---

**Last Review Date:** December 12, 2025

---

### Xyrem

#### Description

Xyrem (sodium oxybate)

---

#### Background

Xyrem (sodium oxybate) is a central nervous system depressant used for the treatment of cataplexy in narcolepsy or excessive daytime sleepiness. The mechanism of action of Xyrem in the treatment of narcolepsy is unknown. Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB) an endogenous compound and metabolite of the neurotransmitter GABA. It is hypothesized that the therapeutic effects of Xyrem on cataplexy and excessive daytime sleepiness are mediated through GABA<sub>B</sub> actions at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons (1).

#### Regulatory Status

FDA-approved indications: Xyrem is a central nervous system depressant indicated for the treatment of cataplexy in narcolepsy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy (1).

Xyrem includes a boxed warning citing the risks of central nervous system depression and abuse and misuse. Use caution when considering the concurrent use of Xyrem with other CNS depressants. Because of the risks of CNS depression, abuse and misuse Xyrem is available only through a restricted distribution program called the Xywav and Xyrem REMS (1).

Xyrem has warnings for depression and suicidality, confusion/anxiety, parasomnias and high sodium content in Xyrem. In addition, patients should be instructed to not engage in activities

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2026
<b>Subsection:</b>	Central Nervous System Drugs	<b>Original Policy Date:</b>	June 6, 2014
<b>Subject:</b>	Xyrem	<b>Page:</b>	2 of 6

---

requiring mental alertness or motor coordination, including operating hazardous machinery, for at least 6 hours after taking Xyrem (1).

Xyrem is contraindicated in patients with succinic semialdehyde dehydrogenase deficiency and in combination with sedative hypnotics or alcohol (1).

Safety and effectiveness of Xyrem in patients less than 7 years of age have not been established (1).

---

## Related policies

Hetlioz, Lumryz, Orexin Antagonists, Rozerem, Sedative Hypnotics, Xywav

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Xyrem may be considered **medically necessary** if the conditions indicated below are met.

Xyrem may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 7 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

1. Cataplexy in narcolepsy
2. Excessive daytime sleepiness (EDS) in narcolepsy

**AND ALL** of the following:

1. Patient and prescriber are both enrolled in the Xyrem REMS Program
2. Prescriber will monitor for signs of misuse, abuse, and addiction during therapy

**AND NONE** of the following:

1. Succinic semialdehyde dehydrogenase deficiency
2. Concurrent therapy with a Prior Authorization (PA) sleep aid (see Appendix 1) or with another oxybate product (see Appendix 2)

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2026
<b>Subsection:</b>	Central Nervous System Drugs	<b>Original Policy Date:</b>	June 6, 2014
<b>Subject:</b>	Xyrem	<b>Page:</b>	3 of 6

---

## Prior – Approval *Renewal* Requirements

**Age** 7 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

1. Cataplexy in narcolepsy
2. Excessive daytime sleepiness (EDS) in narcolepsy

**AND ALL** of the following:

1. Prescriber will continue to monitor for signs of misuse, abuse, and addiction during therapy
2. **NO** concurrent therapy with another Prior Authorization (PA) sleep aid (see Appendix 1) or with another oxybate product (see Appendix 2)

### Policy Guidelines

#### Pre - PA Allowance

None

## Prior - Approval Limits

**Quantity** 810 grams (1620 ml) per 90 days

**Duration** 6 months

---

## Prior – Approval *Renewal* Limits

**Quantity** 810 grams (1620 ml) per 90 days

**Duration** 12 months

### Rationale

### Summary

Xyrem (sodium oxybate) is a central nervous system depressant used for the treatment of cataplexy in narcolepsy or excessive daytime sleepiness. Xyrem includes a boxed warning

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	January 1, 2026
<b>Subsection:</b>	Central Nervous System Drugs	<b>Original Policy Date:</b>	June 6, 2014
<b>Subject:</b>	Xyrem	<b>Page:</b>	4 of 6

---

citing the risks of central nervous system depression and abuse and misuse. Xyrem has warnings for depression and suicidality, confusion/anxiety, parasomnias, and high sodium content in Xyrem. Xyrem is available only through a restricted distribution program called the Xywav and Xyrem REMS. Safety and effectiveness of Xyrem in patients less than 7 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Xyrem while maintaining optimal therapeutic outcomes.

## References

1. Xyrem [package insert]. Palo Alto, CA: Jazz Pharmaceuticals Inc.; July 2025.

## Policy History

Date	Action
May 2014	New addition to PA
September 2014	Annual review
June 2015	Annual review
September 2016	Annual editorial review and reference update Policy number change from 5.07.11 to 5.60.05
December 2017	Annual editorial review and reference update Addition of age to renewal
November 2018	Annual editorial review and reference update Age limit decreased to 7 years or older
December 2019	Annual review
May 2020	Revised no dual therapy requirement
June 2020	Annual review
March 2021	Annual editorial review and reference update
May 2021	Added no dual therapy with another oxybate product
June 2021	Annual editorial review. Revised Appendix 1
September 2022	Annual editorial review and reference update. Added Quviviq to Appendix 1
September 2023	Annual review and reference update
December 2023	Annual review
December 2024	Annual editorial review
December 2025	Annual review and reference update

## Keywords

# 5.60.005

---

**Section:** Prescription Drugs      **Effective Date:** January 1, 2026  
**Subsection:** Central Nervous System Drugs      **Original Policy Date:** June 6, 2014  
**Subject:** Xyrem      **Page:** 5 of 6

---

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 12, 2025 and is effective on January 1, 2026.**

---

**Section:** Prescription Drugs      **Effective Date:** January 1, 2026  
**Subsection:** Central Nervous System Drugs      **Original Policy Date:** June 6, 2014  
**Subject:** Xyrem      **Page:** 6 of 6

---

### Appendix 1 - List of Prior Authorization (PA) Sleep Aids

Generic Name	Brand Name
daridorexant	Quviquq
estazolam	Prosom
eszopiclone	Lunesta
flurazepam	Dalmane
lemborexant	Dayvigo
quazepam	Doral
ramelteon	Rozerem
tasimelteon	Hetlioz
suvorexant	Belsomra
temazepam	Restoril
triazolam	Halcion
zaleplon	Sonata
zolpidem	Ambien
zolpidem extended-release	Ambien CR
zolpidem oral spray	Zolpimist
zolpidem sublingual	Edluar
zolpidem sublingual	Intermezzo

### Appendix 2 - List of Oxybate Products

Generic Name	Brand Name
sodium oxybate	Lumryz
sodium oxybate	Xyrem
calcium, magnesium, potassium, sodium oxybates	Xywav